Laurie Villanueva

Laurie Villanueva has been writing about consumer issues for over two decades, Her work for largely focuses on pharmaceutical and medical device safety, including the ongoing litigation surrounding Risperdal, proton pump inhibitors, Invokana, Levaquin, defective hip implants, the Bair Hugger forced air warming blanket, and IVC filters. Laurie has also devoted a great deal of coverage to women’s health issues, especially recent litigation involving talcum powder, power morcellators, transvaginal mesh, and breast implants.

Laurie graduated from Penn State University in 1990 with a degree in journalism. After spending many years covering local government for various print media outlets, she is now focused on utilizing the internet to raise awareness about important consumer issues.

Child Victims Act Plaintiffs May Remain Anonymous, New York Judge Rules

Plaintiffs filing lawsuits in accordance with New York’s recently passed Child Victim’s Act got a bit of a boost this week, when a New York City judge ruled they may remain anonymous. New York Child Victims Act Ruling Applies Statewide … Continue reading

Zantac Recalls Poised to take Significant Bite Out of Pharma’s Profits

At least one drug maker has incurred a significant financial hit because of recent recalls involving Zantac and other ranitidine-containing heartburn medications, a possible sign of what might await others in the pharmaceutical industry. Dr. Reddy’s Sales Down 25% Due to … Continue reading

Valsartan Recall Triggered Jump in Emergency Room Visits

A newly published study suggests the recent recalls involving valsartan and other contaminated blood pressure medications might have triggered a significant increase in emergency room visits. How the Valsartan Recall Study Was Conducted The study, which was published this week … Continue reading

Health Canada Issues New Warning for Uloric Heart Problems

Uloric (febuxostat) has lost first-line status in Canada, after a study suggested the gout treatment is associated with an increased risk of cardiovascular death and other heart problems. Uloric Heart Problems: Background Uloric is marketed by Takeda Pharmaceuticals to lower … Continue reading

Federal Government Sues Gilead Over HIV PrEP Patents

The United States government has filed suit against Gilead Sciences, Inc., alleging certain HIV drug patents actually belong to the nation’s taxpayers. ““HHS recognizes Gilead’s role in selling Truvada and Descovy to patients for prevention of HIV.  Communities have put … Continue reading

Aurobindo Announces Generic Zantac Recall

Aurobindo Pharma USA has become the latest drug maker to announce a Zantac-related recall amid concerns that ranitidine-containing heartburn drugs might be contaminated with a cancer-causing chemical. 7th Zantac-Related Recall Since September This latest recall – the seventh since September … Continue reading

FDA Announces Class I Recall for Zimmer Biomet Robotic Surgery System

The U.S. Food & Drug Administration (FDA) has announced a Class I medical device recall for Zimmer Biomet’s ROSA Brain 3.0 Robotic Surgery System. According to a recall notice posted to the agency’s website on November 7th, a software issue … Continue reading

Zantac Studies Pointed to NDMA Risk in 1980s

As regulators and researchers around the world rush to determine if Zantac poses a cancer risk, a new report indicates the potential danger was recognized as early as the 1980s. Zantac and NDMA Drug makers have been recalling name-brand and … Continue reading

Initiative Aims to Combat Sex Trafficking During Miami Super Bowl

Super Bowl LIV is still months away, but officials in Miami, Florida are working to combat sex trafficking before this season’s big event. The Super Bowl is notorious for attracting sex traffickers, many of whom will exploit children younger than … Continue reading

New York Pharmacies Must Now Inform Patients of Certain Drug Recalls

Pharmacies across New York must now inform customers whenever a prescription medication is subject to a Class I drug recall. Signed last month by Governor Andrew Cuomo, the new law requires that patients be notified within three days of a … Continue reading

Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest